Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries
- 668 Downloads
The modalities and contributions to drug safety of patient adverse drug reaction reporting systems in 50 countries have been reviewed and analysed.
The means made available by National Health Competent Authorities (NCAs) for patients to report drug side effects were compared through literature review and questionnaire.
Among the 50 countries included in this study, we found that direct patient reporting systems exist in 44 countries and represent 9 % of total reports, the rest coming from healthcare professionals. Australia was the first, in 1964, and the United States has the system in which patients are the most involved. A total of 27 countries have a patient-specific reporting form, and 31 countries provide a form to complete online. In order to help patients, four countries constrain the description of the reaction and 12 constrain the choice of drug on the reporting form. Most of the surveyed countries request the patient’s medical history (30 countries) and concomitant therapies (41 countries). The total number of fields per form ranges from 6 to 59, with a mean of 36 items.
Most of the surveyed countries have implemented a patient adverse drug reaction reporting system. From this study, it seems that an online reporting form increases the rate of reporting. Currently, many different forms exist worldwide; these should be harmonized by considering the strengths and weaknesses of all existing forms. But above all, to increase the number of reports, each country should promote NCA-initiated adverse drug reactions reporting systems.
KeywordsHealthcare Professional Adverse Drug Reaction Varenicline Adverse Drug Reaction Reporting International Drug Monitoring
Funding and conflicts of interest
No sources of funding were used to assist in the preparation of this study. Florence Margraff and Delphine Bertram have no conflicts of interest that are directly relevant to the content of this study.
- 1.REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products; 2010. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2010_1235/reg_2010_1235_en.pdf. Accessed 21 Oct 2013.
- 2.DIRECTIVE 2010/84/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use; 2010. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF. Accessed 21 Oct 2013.
- 3.Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use—article 107a. Official Journal L. 2004;311:67–128.Google Scholar
- 4.World Health Organization website. http://apps.who.int/medicinedocs/fr/d/Jh1465e/4.html. Accessed 20 Sept 2013.
- 8.Herxheimer A, Crombag R, Alves TL. Direct patient reporting of adverse drug reactions: a fifteen-country survey and literature review. Health Action International Europe; 2010. http://www.haiweb.org/10052010/10_May_2010_Report_Direct_Patient_Reporting_of_ADRs.pdf. Accessed 20 Jun 2013.
- 9.Cumber SL, Heffer SJ, Gandhi S, Avery AJ. The Yellow Card Scheme: experience of patient reporting of adverse drug reactions 5 years since launch. Pharmacoepidemiol Drug Saf. 2010;19:S321.Google Scholar
- 13.Hazell L, Cornelius V, Shakir S, Avery AJ. Patient reporting of adverse drug reactions in the UK: potential signals generated by patients compared to healthcare professionals [poster abstract no. 227]. Pharmacoepidemiol Drug Saf. 2010;19(Suppl. 1):S97–8.Google Scholar
- 20.http://www.who-umc.org/DynPage.aspx?id=98080&mn1=7347&mn2=7252&mn3=7322&mn4=7324. Accessed 20 Mar 2014.
- 23.http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf. Accessed 20 Mar 2014.
- 24.The Erice declaration: the critical role of communication in drug safety. Hugman B Drug Saf. 2006;29(1):91–3.Google Scholar
- 25.Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234, iii–iv.Google Scholar
- 27.Irish Medicines Board. Tract “Medicines and side effects”. http://www.imb.ie/images/uploaded/documents/SideEffects.pdf. Accessed 3 Nov 2013.
- 28.9th Call for Proposals 2013—Innovative Medicines Initiative—IMI/DORA_2013-03180. http://www.imi.europa.eu. Accessed 29 Oct 2013.
- 31.Chiahemen T. Interview: how NAFDAC checkmates adverse drug reaction with PRASCOR—Mrs. Osakwe. National Accord Newspaper; 2013.Google Scholar